BRIEF-Agenus to start the phase 1/2 clinical trial of anti-OX40
November 30, 2016 at 09:25 AM EST
* Agenus announces commencement of phase 1/2 clinical trial of anti-OX40 checkpoint antibody INCAGN1949 in patients with solid tumors
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.